Dermatitis

Announcing the Digital In Vivo Alliance (DIVA), a precompetitive consortium to develop, validate and promote the use of AI-enabled digital biomarkers in preclinical in vivo research.

Retrieved on: 
Thursday, October 19, 2023
Digital, Biomarker, DVM, Calico (company), Respiratory disease, Doctor of Philosophy, Research, Multimedia, Public sector, BioMarin Pharmaceutical, Novartis, Machine learning, DIVA, Algorithm, AbbVie, Jackson Laboratory, AI, Epilepsy, Patient, Dermatitis, SAN, Medical imaging, Vaccine

DIVA has the mission to collaboratively advance digital biomarkers for preclinical in vivo research through their development, validation, adoption, and regulatory acceptance.

Key Points: 
  • DIVA has the mission to collaboratively advance digital biomarkers for preclinical in vivo research through their development, validation, adoption, and regulatory acceptance.
  • Digital In Vivo Alliance members work together non-competitively, for the purpose of exploring preclinical applications of AI-enabled digital biomarkers from home cage-compatible technologies.
  • This collaborative approach serves to accelerate the understanding and integration of digital biomarkers in preclinical models, fortifying our shared vision of enabling novel therapies through the adoption of digital biomarkers in AI-enhanced in vivo research.
  • Inquiries about DIVA and the discovery, development, and adoption of digital biomarkers can be directed to the Digital In Vivo Alliance using the contact information below or at DIVA.bio .

Kao Announces the Launch of re/cover A First of Its Kind Eczema Relief System

Retrieved on: 
Wednesday, October 18, 2023
Adhesive, Skin, Aesculus, Dermatitis, Allantoin, Paraben, Kao, Serum, Avenanthramide, Pharmaceutical industry, Cosmetics

With a steadfast commitment to consumer well-being, Kao has developed a revolutionary system featuring patented technology that provides eczema relief while addressing the pain points often associated with existing treatments on the market.

Key Points: 
  • With a steadfast commitment to consumer well-being, Kao has developed a revolutionary system featuring patented technology that provides eczema relief while addressing the pain points often associated with existing treatments on the market.
  • re/cover represents a paradigm shift in the field of eczema management, offering a steroid-free, safe and highly effective solution that is accessible to consumers.
  • The system features a Calming Eczema Serum designed to relieve the itch paired with an invisible protective Moisture Patch to help recover healthy-looking skin.
  • "The launch of re/cover is a milestone moment for Kao," says Karen Frank, President, Consumer Care Business, Americas and EMEA.

EAACI Pediatric Allergy and Asthma Meeting 2023: Shaping the Future of Pediatric Allergy and Asthma Care

Retrieved on: 
Tuesday, October 17, 2023
Union, Parent, School, Asthma, EAACI, Anxiety, Allergic rhinitis, Risk, Travel, Immunodeficiency, Dermatitis, Farm Labor Organizing Committee, PAAM, Immunomodulation, Congress, Food, Anaphylaxis, Research, Risk assessment, Nursing, Vaccine

ZURICH, Oct. 17, 2023 /PRNewswire/ -- The Organizing Committee is thrilled to announce the eagerly anticipated EAACI Pediatric Allergy and Asthma Meeting (PAAM) 2023, scheduled to take place from 2nd to 4th November 2023.

Key Points: 
  • ZURICH, Oct. 17, 2023 /PRNewswire/ -- The Organizing Committee is thrilled to announce the eagerly anticipated EAACI Pediatric Allergy and Asthma Meeting (PAAM) 2023, scheduled to take place from 2nd to 4th November 2023.
  • This event will bring together esteemed experts from around the world to address the pressing challenges and advancements in the field of pediatric allergy and asthma.
  • Allergy often manifests as a multi-system disorder in children with co-existing conditions such as allergic rhinitis, eczema, and food allergies.
  • These conditions can significantly impact a child's daily life, affecting their school performance, travel, dietary choices, sleep patterns, and social interactions.

EAACI Pediatric Allergy and Asthma Meeting 2023: Shaping the Future of Pediatric Allergy and Asthma Care

Retrieved on: 
Tuesday, October 17, 2023
Union, Parent, School, Asthma, EAACI, Anxiety, Allergic rhinitis, Risk, Travel, Immunodeficiency, Dermatitis, Farm Labor Organizing Committee, PAAM, Immunomodulation, Congress, Food, Anaphylaxis, Research, Risk assessment, Nursing, Vaccine

ZURICH, Oct. 17, 2023 /PRNewswire/ -- The Organizing Committee is thrilled to announce the eagerly anticipated EAACI Pediatric Allergy and Asthma Meeting (PAAM) 2023, scheduled to take place from 2nd to 4th November 2023.

Key Points: 
  • ZURICH, Oct. 17, 2023 /PRNewswire/ -- The Organizing Committee is thrilled to announce the eagerly anticipated EAACI Pediatric Allergy and Asthma Meeting (PAAM) 2023, scheduled to take place from 2nd to 4th November 2023.
  • This event will bring together esteemed experts from around the world to address the pressing challenges and advancements in the field of pediatric allergy and asthma.
  • Allergy often manifests as a multi-system disorder in children with co-existing conditions such as allergic rhinitis, eczema, and food allergies.
  • These conditions can significantly impact a child's daily life, affecting their school performance, travel, dietary choices, sleep patterns, and social interactions.

Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, Fatal, Weakness, Female, Skin, PD-L1, Creatinine, DKA, Nausea, Swelling, Keratitis, Pneumonia, Birth, PD-1, Hair, Neutrophil, Male, Peripheral neuropathy, Lipase, Acute kidney injury, Blood, Stevens–Johnson syndrome, Toxic epidermal necrolysis, Diabetic neuropathy, Toxicity, Bulla, Temperature, Appetite, Itch, SJS, Fetus, Cornea, Conjunctivitis, Hyperglycemia, Dermatitis, Evaluation, Hypoxia, Pain, Diabetic ketoacidosis, Pembrolizumab, ILD, Risk, Liver, Lymphocyte, Grade 2, Rash, Erythema, Fatigue, Acral lentiginous melanoma, Pneumonitis, Papule, Incidence, Dysgeusia, Anemia, Cough, Urinary tract infection, Diarrhea, Erythroderma, Periodic breathing, TEN, Patient, MUC, PN, Drug eruption, Septic shock, Pharmaceutical industry, Medical imaging, Palladium

Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.

Key Points: 
  • Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.
  • When PADCEV was given in combination with pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate.
  • Skin reactions occurred in 72% (all grades) of the 121 patients treated with PADCEV in combination with pembrolizumab in clinical trials.
  • The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash.

Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria

Retrieved on: 
Thursday, October 12, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CSU, Pharmacokinetics, Therapy, Atopic dermatitis, Safety, Dermatitis, Disease, B cell, Escient, UAS7, Hives, Patient, MRGPRX2, Pharmaceutical industry, Vaccine

Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria (CSU).

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria (CSU).
  • By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell mediated diseases with an initial focus on chronic urticaria (hives) and atopic dermatitis (eczema).
  • EP262 represents a novel, targeted approach to the treatment of these disorders with the potential for once-daily oral administration without the side effects observed with other approaches.
  • The primary efficacy endpoint is the change from baseline in the urticaria activity score over 7 days (UAS7), a validated and widely used measure of disease activity.

Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity

Retrieved on: 
Wednesday, October 11, 2023
Entertainment, Biotechnology, Celebrity, Other Education, Health, Music, Pharmaceutical, General Health, Education, Diagnosis, Multimedia, Partnership, Human, Inflammation, Dermatology, Atopic dermatitis, Dermatitis, Disease, Moments of Clarity, AD, Skin, Patient, Nursing, Clarity

View the full release here: https://www.businesswire.com/news/home/20231011336627/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231011336627/en/
    As someone who also lives with eczema, Mandy Moore understands the challenges of the condition.
  • Through Moments of Clarity, Mandy encourages others with eczema to take charge of their health and talk to their dermatologists about finding an appropriate treatment.
  • After seeing a dermatologist, I was diagnosed with eczema," said Mandy Moore.
  • “We are grateful to Mandy Moore for partnering with us and lending her voice to help others know they are not alone in their journeys.”
    * Mandy Moore has been compensated for her participation.

Virtual Asthma Coaching Found to Improve Asthma Control

Retrieved on: 
Tuesday, October 3, 2023
Amgen, Partnership, Asthma, Network, Education, Hospital, Regeneron Pharmaceuticals, Health, Dermatitis, Native, COVID-19, Food, Health equity, Quality of life, Human, Allergy, AstraZeneca, COVID-19 testing, Messenger, Novartis, Risk, Disease, Sanofi, Mortality, Death, Pharmaceutical industry, Genentech

FAIRFAX, Va., Oct. 3, 2023 /PRNewswire/ -- Adults with uncontrolled asthma who take part in virtual asthma coaching show improved asthma control and quality of life, and experience fewer doctor or emergency department visits. Those are the key findings of a new impact report summarizing Allergy & Asthma Network's innovative Virtual Asthma Coaching program.

Key Points: 
  • Those are the key findings of a new impact report summarizing Allergy & Asthma Network's innovative Virtual Asthma Coaching program.
  • The Virtual Asthma Coaching program is part of Trusted Messengers, Allergy & Asthma Network's largest health equity initiative.
  • "Our Virtual Asthma Coaching program saves lives," says Lynda Mitchell, CEO of Allergy & Asthma Network.
  • The Virtual Asthma Coaching program began in 2020 as a pilot program during Allergy & Asthma Network's response to the COVID-19 pandemic.

Board-certified Dermatologist Dr. Blair Rose Announces the Launch of Skincare Junkie

Retrieved on: 
Tuesday, October 3, 2023
Weill Cornell Medical Center, Rosacea, Montefiore Medical Center, University, Shareasale, Helsinki University Central Hospital, Business Insider, Salicylic acid, Cowra breakout, Dermatitis, University of California, Irvine School of Medicine, Antioxidant, Merchant, Skin cancer, Pediatric Dermatology, Vogue, Skin, Phthalate, Women's health, American Academy, Hyaluronic acid, Acne, Multimedia, FAAD, Pore, Psoriasis, John Foster Dulles, Journal, PHA, Publication, PRP, Patient, Irritation, Confusion, Albert Einstein College of Medicine, Ceramide, Cosmetics, Dermatology, Elle, MD, Medicine

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Board certified and award-winning dermatologist Dr. Blair Rose is excited to share the launch of Skincare Junkie , a skincare line that utilizes powerful and clinically proven ingredients in just the right combinations and concentrations to solve common skin problems.

Key Points: 
  • NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Board certified and award-winning dermatologist Dr. Blair Rose is excited to share the launch of Skincare Junkie , a skincare line that utilizes powerful and clinically proven ingredients in just the right combinations and concentrations to solve common skin problems.
  • Dr. Rose created Skincare Junkie out of necessity when she noticed countless patients developing breakouts and skin irritation from popular skincare products.
  • "I needed to create a line of non-toxic, hypoallergenic skincare that I would feel confident suggesting to my patients and that they would enjoy using" says Dr. Rose.
  • Blair Murphy Rose, MD, FAAD , is an award-winning board-certified dermatologist seeing patients in NYC and a clinical instructor of dermatology at the Weill Cornell Medical Center.

The Inner Circle Acknowledges, Jason Chouake as a Most Trusted Healthcare Professional for his contributions to the field of Dermatology

Retrieved on: 
Friday, September 29, 2023
American Academy of Dermatology, Travel, Physician, Education, Dermatitis, Skin cancer, American Academy, Moles, Multimedia, Inner circle, Psoriasis, Yeshiva University, Montefiore, Family, Dermatology

CLIFFSIDE PARK, N.J., Sept. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jason Chouake is acknowledged as a Most Trusted Healthcare Professional for his contributions to the field of Dermatology.

Key Points: 
  • CLIFFSIDE PARK, N.J., Sept. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jason Chouake is acknowledged as a Most Trusted Healthcare Professional for his contributions to the field of Dermatology.
  • He later earned a Medical Doctor degree from Albert Einstein School of Medicine, Montefiore, where he also completed his residency in Dermatology.
  • A fellow of the American Academy of Dermatology, the doctor has extensive experience in Skin Cancer and Excision; Cosmetic Skin Procedures; and Skin Conditions.
  • Aside from his professional pursuits, Dr. Chouake likes to spend time with his family and travel.